{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T14:03:24Z","timestamp":1780841004551,"version":"3.54.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.clml.2021.05.006","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T12:38:15Z","timestamp":1621427895000},"page":"e726-e730","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Impact of Prior Salvage Treatment With Immune Checkpoint Inhibitors on Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Single-Center Experience"],"prefix":"10.1016","volume":"21","author":[{"given":"Jiyeon Joy","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale G","family":"Schaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.05.006_bib0001","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/imm.12788","article-title":"PD-1\/PD-L1 inhibitors in haematological malignancies: update 2017","volume":"152","author":"Jelinek","year":"2017","journal-title":"Immunology"},{"key":"10.1016\/j.clml.2021.05.006_bib0002","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s11899-020-00589-y","article-title":"PD-1\/PD-L1 pathway and its blockade in patients with classic Hodgkin lymphoma and non-Hodgkin large-cell lymphomas","volume":"15","author":"Xie","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2021.05.006_bib0003","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.05.006_bib0004","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.006_bib0005","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.006_bib0006","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","article-title":"Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1\/2 trial","volume":"7","author":"Diefenbach","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2021.05.006_bib0007","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/sj.bmt.1703015","article-title":"Engraftment syndrome following hematopoietic stem cell transplantation","volume":"27","author":"Spitzer","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.05.006_bib0008","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.bbmt.2015.08.030","article-title":"Engraftment syndrome after autologous stem cell transplantation: an update unifying the definition and management approach","volume":"21","author":"Cornell","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.05.006_bib0009","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/s41409-020-01164-y","article-title":"Prior anti-PD-1 therapy as a risk factor for life-threatening peri-engraftment respiratory distress syndrome in patients undergoing autologous stem cell transplantation","volume":"56","author":"Bai","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.05.006_bib0010","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.bbmt.2013.06.017","article-title":"Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma","volume":"19","author":"Cornell","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.05.006_bib0011","doi-asserted-by":"crossref","first-page":"e13797","DOI":"10.1111\/ctr.13797","article-title":"Postautologous stem cell transplantation engraftment syndrome: improved treatment and outcomes","volume":"34","author":"Liu","year":"2020","journal-title":"Clin Transplant"},{"key":"10.1016\/j.clml.2021.05.006_bib0012","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/sj.bmt.1703075","article-title":"Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation","volume":"27","author":"Capizzi","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.05.006_bib0013","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/bmt.2014.296","article-title":"Engraftment syndrome: double-edged sword of hematopoietic cell transplants","volume":"50","author":"Spitzer","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.05.006_bib0014","first-page":"1","article-title":"Engraftment syndrome: an updated review","volume":"1","author":"Mutaher","year":"2017","journal-title":"J Stem Cell Biol Transplant"},{"key":"10.1016\/j.clml.2021.05.006_bib0015","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3324\/haematol.2015.132761","article-title":"The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints","volume":"101","author":"Vardhana","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.05.006_bib0016","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nri3740","article-title":"T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?","volume":"14","author":"Speiser","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.clml.2021.05.006_bib0017","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41577-019-0223-7","article-title":"Precursor exhausted T cells: key to successful immunotherapy?","volume":"20","author":"Kallies","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.clml.2021.05.006_bib0018","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.clml.2021.05.006_bib0019","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clml.2021.05.006_bib0020","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.clml.2021.05.006_bib0021","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.clml.2021.05.006_bib0022","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.immuni.2016.07.021","article-title":"T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections","volume":"45","author":"Utzschneider","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.clml.2021.05.006_bib0023","doi-asserted-by":"crossref","first-page":"eaai8593","DOI":"10.1126\/sciimmunol.aai8593","article-title":"The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness","volume":"1","author":"Wu","year":"2016","journal-title":"Sci Immunol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021001932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021001932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:36:49Z","timestamp":1761871009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021001932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S2152265021001932"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.05.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of Prior Salvage Treatment With Immune Checkpoint Inhibitors on Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Single-Center Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}